Neurocrine’s New Tardive Dyskinesia Trial Adds Fresh Optionality for NBIX Investors

Neurocrine Biosciences (NBIX) announced an update on their ongoing clinical study.

Neurocrine Biosciences is running a Phase 2 study called “A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia.” The goal is to see if its new drug can reduce involuntary movements in adults with tardive dyskinesia and to gauge safety and tolerability.

The main treatment is an oral drug called NBI-1065890, developed by Neurocrine Biosciences for tardive dyskinesia. A matching placebo is used as a control, so any change in symptoms can be clearly linked to the drug and not to expectations or other factors.

The study is interventional, with patients randomly assigned to NBI-1065890 or placebo, in parallel groups. It is double-blind at four levels, meaning patients, doctors, study staff, and outcome assessors do not know who is getting the active drug, and the main aim is to test treatment benefit.

The study is listed as recruiting, showing it is still in the enrollment phase. It was first submitted on January 22, 2026, and the record was last updated on May 18, 2026, giving investors a recent signal that setup and site activation are progressing.

For investors, this update signals that Neurocrine is pushing deeper into movement disorder drugs beyond its approved tardive dyskinesia product, which may support long-term growth narratives. Success in this trial could strengthen NBIX’s competitive edge against other central nervous system players and improve sentiment, though trial risk and timelines mean near-term stock moves may stay modest.

The study is ongoing and recently updated, with more details available on the ClinicalTrials portal.

To learn more about NBIX’s potential, visit the Neurocrine Biosciences drug pipeline page.